Global Biopharma Layoffs January 2026LayoffsThis article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Gilead Q2 2025 Financial ReportFinancial statementsGilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
Sanofi and Gilead Expand Protein Degrader PortfoliosSanofiSanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
Global Biopharma Layoffs June 2025 LayoffsBiopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
FDA Puts Gilead’s HIV Combo Trials on HoldGileadThe FDA has paused five Gilead HIV combo trials over safety concerns, but the decision does not impact lenacapavir's upcoming PrEP approval. Gilead remains confident in its HIV pipeline and future plans.
Trodelvy Shows Strong Solo Efficacy in TNBCGileadGilead’s Trodelvy shows significant solo efficacy in the ASCENT-03 trial, outperforming chemotherapy in previously untreated TNBC patients not eligible for immunotherapy.
Gilead's Q1 2025 Financial report Financial statementsGilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
Global Biopharma Layoffs April 2025LayoffsStay updated on recent global biopharma layoffs in April 2025. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
2024 Global CAR-T Sales PerformanceCAR-TDiscover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
Biotech Giants Performance Comparison 2024Market TrendCompare the 2024 financial performance of top biotech giants, including Vertex, Amgen, Gilead, Regeneron, and Biogen. Explore revenue, net profit, R&D investment, and market trends shaping the biotech industry.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
